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Abstract
Background: Diabetes is associated with an increased risk of several malignancies. Both diabetic patients and patients 
with cancer have an increase in platelet reactivity and platelet activation has recently emerged as a potential mediator 
of cancer progression. Drug therapies, such as aspirin, that reduce platelet reactivity reduce both cardiovascular and 
cancer risk.
Methods: We performed a cross-sectional analysis to assess the association between history of cancer and current 
anti-platelet drug use in a primary care population of adults with diabetes enrolled in the Vermont Diabetes 
Information System.
Results: Self-reported characteristics, medical history, and a complete medication list were recorded on 1007 diabetic 
adults. Fifty percent of diabetic patients used an anti-platelet drug. In unadjusted analysis, no association was seen 
between anti-platelet drug use and cancer history (OR = 0.93; P = .70). Platelet inhibitor use was associated with a 
decreased patient-reported history of malignancy in a multivariate logistic regression adjusted for age, sex, body mass 
index, comorbidity, and number of medications (OR = 0.66; CI 0.44-0.99; P = .045). Similar odds of association were seen 
in both males and females, and for aspirin and non-aspirin platelet inhibitor therapy.
Conclusions: Our data suggest an association between anti-platelet drug use and reduced cancer prevalence in 
patients with diabetes. Given the potentially large implications of our observations in the diabetic population, further 
studies are required to determine if this association is causal.
Background
Epidemiologic studies have found an increase in cancer
mortality and risk of several cancer types in persons with
type 2 diabetes mellitus[1-4]. The association is likely
multifactorial and may be mediated by insulin resistance
and the metabolic syndrome as well as common life-style
choices and obesity[5,6]. Patients with diabetes com-
monly display an increase in platelet reactivity [7], and
large studies have suggested they derive particular car-
diovascular benefit from platelet inhibition [8]. Accumu-
lating evidence also suggests a role for platelet activation
in cancer progression and an increase in platelet reactiv-
ity has been seen in patients with metastatic cancer [9-
11].
The use of aspirin, an inhibitor of platelet reactivity, is
associated with cancer prevention in two of the most
common solid tumor malignancies affecting patients with
diabetes: colorectal and breast cancer. The efficacy of
aspirin in cancer prevention has been linked in part to
inhibition of COX-2 (inducible) driven pathways of
malignancy development (reviewed in [12]). In murine
models, however, thrombocytopenia and platelet antago-
nists decrease tumor metastases indirectly supporting a
plausible role for COX-1 platelet inhibition in cancer pre-
vention and treatment [13,14].
Given the role of aspirin in cancer prevention in the
general population, the increase in platelet reactivity in
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diabetics, and the emerging role of platelet activity in
cancer progression, we explored the association between
anti-platelet drug use and cancer history in persons with
type 2 diabetes. We hypothesized that persons with type
2 diabetes taking anti-platelet drugs such as aspirin
would have a decreased risk of cancer compared to dia-
betic persons not using aspirin.
Methods
The Vermont Diabetes Information System was a ran-
domized trial of a decision support system in diabetes
[15]. All diabetic adults in 69 primary care practices in
Vermont and adjacent New York were enrolled. Following
ascertainment of informed consent, a randomly selected
subset of 1007 subjects completed a survey and a home
visit by trained researchers between July 2003 and March
2005. Patients were asked to gather all current media-
tions, including over the counter drugs. Staff recorded
the drug name, dose, frequency, and route of administra-
tion from each container . Duration of therapy was not
ascertained. Weight and height were recorded using a
portable stadiometer and scale.
Patient characteristics were obtained by questionnaire.
Comorbidity (in addition to diabetes) was determined
using a modification of the Self-Administered Comorbid-
ity Questionnaire [16]. Patients who reported a history of
any malignancy, including leukemia or lymphoma, were
classified as having cancer. Dates of diagnosis, treat-
ments, and site were not recorded. A1C was measured
using high performance liquid chromatography or a
Bayer DCA 2000 immunoassay point of care instrument
(less than 1% of tests). Anti-platelet drug use was defined
as daily use of aspirin (at least 75 mg), clopidogrel, ticlopi-
dine, or cilostazol or a combination of these medications.
The specific indication for anti-platelet therapy was not
recorded.
We performed a cross-sectional association analysis of
the interviewed subjects at the time of their enrollment in
the VDIS trial. We explored the association between can-
cer and the use of anti-platelet agents, using logistic
regression with history of cancer as the outcome variable
and the use of anti-platelet drugs as the primary predictor
variable. We then adjusted for possible confounding by
social and clinical factors. Potential confounders tested
were: gender, age, race (white/other), glycosylated hemo-
globin level (A1C;mg%), insulin use (yes/no), body mass
index (BMI;kg/m2), alcohol drinking (yes/no), cigarette
smoking (yes/no), income (in eight ordered categories),
duration of diabetes in years, high comorbidity (two or
more comorbid conditions, number of medications,
physical function status and mental function status. To
reduce the number of variables in the final model, we
excluded potential confounders that were associated with
the outcome in univariate analysis with P > 0.2. The final
multivariate analysis adjusted for age, sex, body mass
index, presence of multiple co-morbidities and number of
medications. In secondary analyses, we studied selected
subgroups of patients based on sex and use of different
platelet inhibitors. Association was expressed as the odds
ratio (OR) with 95% confidence interval (CI).
All research was carried out according to the Helsinki
declaration per the University of Vermont Institutional
Review Board.
Results
Selected characteristics of the study population (1,007
subjects) based on anti-platelet drug users versus non-
users are described in Table 1. Half of the population
were seniors, two thirds were obese, and 48% had an A1C
> 7%. There was little racial diversity, reflecting the local
population. Thirteen percent of patients reported a his-
tory of malignancy . Half of the patients used a platelet
inhibitor (aspirin or non-aspirin platelet inhibitor). Aspi-
rin use in this population has previously been found to be
more prevalent in subjects with coronary artery disease
and in men [17].
In unadjusted analysis, no significant association was
seen between anti-platelet drug use and cancer history
(OR = 0.93; CI = (0.64, 1.34); P = .70), Table 1. However,
an unadjusted analysis revealed a significant association
between cancer history and age, more than one comorbid
condition, BMI and number of prescriptions medications
(p ≤ 0.05). In this same analysis, sex, ethnicity, use of insu-
lin therapy, hemoglobin A1C, alcohol use, median
income, duration of diabetes, number of anti-diabetic
medications and physical functional status were not asso-
ciated with a diagnosis of cancer.
A multivariate analysis adjusting for confounding vari-
ables revealed significantly lower odds of a cancer history
among anti-platelet drug users (OR = 0.66; CI 0.44-0.99,
Table 2). Because aspirin use was more common in men
and some cancers are sex-associated, we repeated the
analyses for each sex. The magnitude of the association
was maintained in both males and females; however, the
confidence intervals broadened with the smaller sample
size. The association between anti-platelet drug use and
reduced cancer history was not maintained in persons
under the age of 65 years but was of significance in per-
sons over the age of 65 years (P = 0.047).
The individual anti-platelet drugs studied have distinct
characteristics. For instance, aspirin inhibits platelets and
inhibits COX pathways in tissues and tumors but the oth-
ers do not. To exclude the possibility that the apparent
protective effect of these medications is due to a medica-
tion-specific characteristic (other than anti-platelet activ-
ity), we divided the treatments into two groups (aspirin
and non-aspirin platelet inhibitors) and repeated the
analysis excluding any subjects who used one or the otherHolmes et al. BMC Cancer 2010, 10:289
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Table 1: Characteristics of 1007 study subjects
nM e a nR a n g e nM e a n R a n g e P
Anti-platelet therapy Absent Present
Age in years 499 62.1 22.2-89.5 508 67.6 36.0-92.6 < .001
Gender: male 499 39.7% 508 51.6% < .001
Race: white, 497 96.6% 507 98.0% .15
Body mass index in kg/m2 492 34.5 16.1-64.6 502 33.1 15.8-68.0 .003
Glycosylated hemoglobin A1C 497 7.1% 4.0-13.5 506 7.1% 4.9-12.9 .85
More than 1 comorbid condition 499 45.1% 508 53.5% .007
Current smoker 498 18.5% 508 15.4% .19
Number of medications 499 7.7 0-29 508 9.8 1-29 < .001
Self-reported history of malignancy 499 13.0% 508 12.2% .70
History of cancer Absent Present
Age in years 880 65.2 22.2-91.7 127 69.1 34.5-92.6 < .001
Gender: male 880 46.2% 127 41.7% .34
Race: white, 878 97.3% 126 97.6% .82
Body mass index in kg/m2 868 34.0 15.8-68.0 126 32.6 19.7-53.8 .05
Glycosylated hemoglobin A1C 876 7.1% 4.0-13.5 127 7.0% 4.8-13.3 .13
More than 1 comorbid condition 880 46.2% 127 71.7 < .001
Current smoker 879 17.8% 127 11.0% .06
Number of medications 880 8.6 0-29 127 9.9 0-29 .003
Anti-platelet therapy 880 50.7% 127 48.8% .70
of the groups (Table 2). Although the smaller sample sizes
again reduced precision, the odds ratios changed little,
indicating that the association is not due to some specific
characteristic of one group of platelet inhibitor.
Discussion
Platelet inhibitors were significantly associated with
reduced odds of a cancer history in adults with diabetes
in our study population. The association was not due to
confounding by age, sex, obesity, or number of medica-
tions or co-morbidities. The odds of association were
similar in men and women and for both aspirin and non-
aspirin platelet inhibitor users although smaller numbers
broadened the observed confidence intervals. Our origi-
nal hypothesis was based on data from multiple studies
supporting the use of aspirin therapy in cancer preven-
tion in selected populations. We chose to focus on
p a t i e n t s  w i t h  d i a b e t e s  b e c a u s e  t h e y  h a v e  a n  i n c r e a s e d
reported cancer risk, an increase in platelet reactivity and
a clear benefit from anti-platelet therapy in the cardiovas-
cular setting. Consistent with our hypothesis, we found a
reduction in reported cancer history was associated with
anti-platelet drug use in a community based diabetic
population.
The strong association between platelet inhibitors and
a history of cancer is apparent only when controlling for
other factors such as age, sex, obesity, and burden of
comorbid conditions. This demonstrates that one or
more of these factors confounds the relationship between
platelet inhibition and cancer. As in all non-experimental
studies, the possibility of additional, unmeasured, con-
founders that further influence the relationship between
platelet inhibition and cancer cannot be excluded. Addi-
tionally, our population was heterogeneous with regards
to cancer type and larger studies and/or cancer specific
studies will be needed to determine an association (if any)
between specific cancer subtypes and aspirin use in
patients with diabetes.
These results are consistent with prior studies in
selected patient populations. For example, aspirin use
prevents the development of colorectal adenomas in
patients with a prior history of these lesions [18]. In addi-
tion, several studies have suggested that aspirin use is
as s oc ia t ed  wi t h  a  r ed u c ed  ris k  o f  b r eas t  ca n c e r [ 1 9 , 2 0] .
However, not all studies of aspirin have demonstrated a
benefit in cancer prevention [21]. Our results are the first
to focus on a diabetic population.Holmes et al. BMC Cancer 2010, 10:289
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We found no difference in our study between male and
female users of platelet inhibitor therapy. This is consis-
tent with the finding that men and women have similar
reductions in platelet reactivity to low dose aspirin ther-
apy [22]. In addition, reductions in cancer risk associated
with aspirin therapy are seen in gender specific cancers
such as prostate cancer and breast cancer [20,23].
Mechanisms that explain the possible association
between anti-platelet therapy and cancer were not
addressed by this study. Although aspirin has COX- and
prostaglandin-mediated tissue effects, the other agents
studied do not, suggesting the effects might be related to
platelet inhibition. In the laboratory, ticlopidine (one of
two non-aspirin platelet inhibits used in our patient pop-
ulation) has been reported to inhibit pulmonary metasta-
s is  of  m e la nom a  as w e ll  as m etastasis  in a  Lewis  lu ng
carcinoma model [24]. No human studies using these
agents to prevent or treat cancer have been reported.
Interestingly, some inhibitors of platelet function such as
glycoprotein IIB-IIIA inhibitors have anti-tumor activity
in animal models and have been found to have greater
platelet inhibitor activity in patients with diabetes than
non-diabetic patients [25].
This study provides the first evidence to suggest anti-
platelet therapy may have an anti-cancer benefit in
patients with diabetes. However, the conclusions are lim-
ited by the cross-sectional design, racial homogeneity of
the subjects, use of unconfirmed cancer diagnoses, and
lack of data on cancer site. In addition, anti-platelet drug
duration or dose of therapy was not available and the
temporal relationship between medication use and can-
cer diagnosis is unknown. While the majority of patients
in our study are anticipated to have Type II diabetes, we
did not collect this data directly and; therefore, were
unable to determine if the demonstrated association is
the same for both type I and type II diabetics.
Conclusions
We found anti-platelet drug use was associated with a
reduced number of reported cancer diagnoses in adults
with diabetes who participated in the Vermont Diabetes
Information System Study. Our results suggest targeting
patient populations with increased platelet activation,
such as patients with diabetes mellitus, may be a useful
strategy to move platelet inhibitors successfully into the
cancer prevention or treatment setting. Our results will
need confirmation in larger, prospective studies given the
c r o s s - s e c t i o n a l  d e s i g n  o f  t h e  s t u d y .  I f  c o n f i r m e d ,  o u r
results suggest patients with diabetes may receive a dual
health benefit from a single, inexpensive drug.
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